ClinicalTrials.gg
CompletedNCT07242469Updated Sep 15, 2026

A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)

A Phase 1 interventional study of MK-1403 + additive coformulation and Placebo + additive coformulation in Diabetes Mellitus, Type 2, sponsored by Merck Sharp & Dohme LLC. Completed at 5 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Merck & Co., Inc.

Enrollment
122nd of 170
53 · median 192
Started
2025
with 1 other
Phase 1
55 of 181
none open now
Registered
181st of 181
by date

Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 122nd largest by enrollment of the 170 interventional ones that give a count, is one of 2 that started in 2025, is one of 55 in phase 1, and was the 181st registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc as a file.
02

Study summary

The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-1403. The study will also measure what happens to MK-1403 in the body of a person with type 2 diabetes (T2D) over time (pharmacokinetic or PK study), and how it affects the amount of high-sensitivity C-reactive protein (hsCRP) in a person's blood.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a confirmed diagnosis of Type 2 diabetes mellitus (T2DM)
  • Has (BMI) between 18 and 40 kg/m\^2, inclusive

Exclusion criteria

Exclusion Criteria:

  • Has Type 1 diabetes mellitus or secondary types of diabetes
  • Has a history of congestive heart failure ( [NYHA] Class 3 or 4)
  • Has history of myocardial infarction, uncontrolled arrhythmias, cardiac revascularization, angina, unstable peripheral arterial disease and/or stroke
  • Has history of cancer ()
  • Has positive test(s) for surface antigen (HBsAg), antibodies, or (HIV)
  • Has a history of gastrointestinal (GI) disease which might affect food and drug absorption, or has had gastric bypass or similar surgery
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Panel A MK-1403 + additive coformulation dose 1

    Participants will receive MK-1403 + additive coformulation dose 1 orally once daily.

    Drug: MK-1403 + additive coformulation

  • Placebo comparator
    Panel A Placebo + additive coformulation dose 1

    Participants will receive Placebo + additive coformulation dose 1 orally once daily.

    Drug: Placebo + additive coformulation

  • Experimental
    Panel B MK-1403 + additive coformulation dose 2

    Participants will receive MK-1403 + additive coformulation dose 2 orally once daily

    Drug: MK-1403 + additive coformulation

  • Placebo comparator
    Panel B Placebo + additive coformulation dose 2

    Participants will receive Placebo + additive coformulation dose 2 orally once daily

    Drug: Placebo + additive coformulation

Interventions

  • DrugMK-1403 + additive coformulation

    MK-1403 + additive coformulation is a co-formulated product of MK-1403 administered orally.

  • DrugPlacebo + additive coformulation

    Placebo + additive coformulation is a co-formulated product of placebo administered orally.

06

What researchers measure

Primary outcomes

  1. Number of participants who experience one or more adverse events (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs will be reported.

    Time frame: Up to approximately 28 days

  2. Number of participants who discontinue study intervention due to adverse events

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 14 days

Secondary outcomes

  1. Change from Baseline in Placebo-Corrected High Sensitivity C-Reactive Protein (hsCRP) Serum Concentration

    Blood samples will be collected to determine the change from baseline in placebo-corrected hsCRP.

    Time frame: Baseline and 24-hours postdose on Day 14

  2. Plasma concentration of MK-1403 at 24 Hours Postdose (C24) on Day 14

    Blood samples will be collected to determine the C24 of MK-1403 in plasma on Day 14.

    Time frame: 24-hour postdose on Day 14

07

Study locations

5 sites
  • Anaheim Clinical Trials ( Site 0006)
    Anaheim, California 92801, United States
  • ProSciento Inc. ( Site 0001)
    Chula Vista, California 91911, United States
  • Advanced Pharma CR, LLC ( Site 0003)
    Miami, Florida 33147, United States
  • QPS-MRA, LLC ( Site 0004)
    South Miami, Florida 33143, United States
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0005)
    Springfield, Missouri 65802, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Sep 2026, 8 months.

Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 8 months is above that.

Counting every sponsor, half of 516 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 21, 2025
StartActual
Dec 22, 2025
Primary completionActual
Sep 2, 2026
CompletionActual
Sep 2, 2026
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07242469
Responsible party
Sponsor
First posted
Nov 21, 2025
Start date
Dec 22, 2025
Primary completion
Sep 2, 2026
Completion
Sep 2, 2026
Last update
Sep 15, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion